The British Menopause Society has responded to the programme with some good comments. Of note:
Re dementia - "Women should be reassured that HRT is unlikely to increase the risk of dementia or to have a detrimental effect on cognitive function in women initiating HRT before the age of 65. However, HRT should not be initiated for the purpose of reducing the risk of dementia in postmenopausal women and at this time, there is not enough evidence to support prescribing HRT for prevention of dementia."
Re Testosterone: "Regarding the role of testosterone, the current indication is for persistent low sexual desire after other contributory factors have been addressed. There is not enough evidence available to support it being prescribed for improving cognitive function, musculoskeletal health or improving bone density."
This is also highlighted with the need:
"To provide adequate resources on the menopausal transition to support women in primary and secondary care.
To support the training of all healthcare professionals in menopause management, by official organisations such as the BMS, RCOG and FSRH.
Raise menopause awareness in the workplace including among all managers and staff.
To facilitate further research into the effects of menopause and HRT on cognition, mood and dementia, and the wider role of androgens such as testosterone in women."
thebms.org.uk/2022/05/bms-comment-on-channel-4-programme-davina-mccall-sex-myths-and-the-menopause/?fbclid=IwAR2WqjJTcdgJ4krdEpf381PlD4zK7yLbbNZEpw-aKO-9BQigyj1yQHd4KaU
In other news I'm now reading that (along with Oestrogel HRT) Ovestin (a local estrogen cream for vaginal atrophy) might be in short supply till July 😒. This will not doubt cause a knock-on effect to other VA treatments www.gov.uk/government/news/three-month-limit-for-three-hrt-products-to-ensure-continued-access